skip to Main Content

Maintenance Rucaparib Shows Benefit in Broader Group of Patients with Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Maintenance rucaparib appeared safe and effective for patients with platinum-sensitive advanced pancreatic cancer with pathogenic variants in BRCA1BRCA2 or PALB2, according to research published in Journal of Clinical Oncology.

“The study expands upon the previously published POLO trial in that we saw benefit in patients with locally advanced disease, those with somatic variants, those with PALB2 variants and histologies beyond adenocarcinoma. Therefore, we have expanded the group of patients for whom maintenance PARP [poly(ADP-ribose) polymerase] inhibitors might be used,” Kim A. ReissMD, assistant program director of the hematology/oncology fellowship program and assistant professor of medicine at Hospital of the University of Pennsylvania, and a HemOnc Today Next Gen Innovator, told Healio. Read more . . . 

Back To Top